Lantern Pharma Reports Fourth Quarter and Year End 2020 Financial Results and Operational Highlights

- RADR® artificial intelligence ("A.I.") platform surpassed 1.2 billion datapoints - Advanced opportunities for LP-184 in glioblastoma, prostate and pancreatic cancers in collaboration with leading cancer research centers - Identified and validated additional genomically-driven cancer indications for LP-184 - Advanced the development of LP-300 with a Phase 2 trial launch in NSCLC planned for Q3 2021 - Initiated Antibody Drug Conjugate ("ADC") program with novel linking and conjugation technology - Strengthened balance sheet following January 2021 public offering of $69.0 million

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here